Abstract
Inclusion of interleukin-1β into complex therapy of severe forms of herpes recurrent, allows to remove very effectively immune disturbances and to prevent occurrence of new infection relapses. Prophylactic prescription of interleukin-1β during remission period of herpes recurrent also demonstrated advisability of the therapy. On the background of therapy with interleukin-1β, 12 patients had remission duration. So, in 10 patients prior to therapy with interleukin-1β, remission duration was 1.5 – 2 months, and after the therapy in 9 of them it increased to 10 – 11 months. In 5 female patients, remission duration was 2 – 3 months, after the treatment using interleukin-1β remission lasted more than 12 months. 3 patients during 2-year follow-up had no relapses at all. Anti-recurrent effect of interleukin-1β is related with immunomodulatory properties of the preparation, consisting of increased content of ripe lymphocytes and active lymphocytes (CD25+), as well as increased values of spontaneous and induced LPS NBT-test.